# Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung

> **NCT05027958** · EARLY_PHASE1 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 17 (actual)

## Conditions studied

- Healthy
- Latent Tuberculosis Infection (LTBI)

## Interventions

- **DRUG:** Tuberculin Purified Protein Derivative

## Key facts

- **NCT ID:** NCT05027958
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-03
- **Primary completion:** 2024-11-07
- **Final completion:** 2024-12-08
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05027958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05027958, "Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05027958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*